JP2017113019A5 - - Google Patents

Download PDF

Info

Publication number
JP2017113019A5
JP2017113019A5 JP2017027825A JP2017027825A JP2017113019A5 JP 2017113019 A5 JP2017113019 A5 JP 2017113019A5 JP 2017027825 A JP2017027825 A JP 2017027825A JP 2017027825 A JP2017027825 A JP 2017027825A JP 2017113019 A5 JP2017113019 A5 JP 2017113019A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017027825A
Other languages
English (en)
Japanese (ja)
Other versions
JP6363747B2 (ja
JP2017113019A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017113019A publication Critical patent/JP2017113019A/ja
Publication of JP2017113019A5 publication Critical patent/JP2017113019A5/ja
Application granted granted Critical
Publication of JP6363747B2 publication Critical patent/JP6363747B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017027825A 2011-04-01 2017-02-17 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体 Expired - Fee Related JP6363747B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01
US61/471,101 2011-04-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014502846A Division JP6170903B2 (ja) 2011-04-01 2012-03-30 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018122610A Division JP2018172411A (ja) 2011-04-01 2018-06-28 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2017113019A JP2017113019A (ja) 2017-06-29
JP2017113019A5 true JP2017113019A5 (enExample) 2017-10-19
JP6363747B2 JP6363747B2 (ja) 2018-07-25

Family

ID=46932389

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014502846A Expired - Fee Related JP6170903B2 (ja) 2011-04-01 2012-03-30 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
JP2017027825A Expired - Fee Related JP6363747B2 (ja) 2011-04-01 2017-02-17 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
JP2018122610A Pending JP2018172411A (ja) 2011-04-01 2018-06-28 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
JP2020176145A Withdrawn JP2021019619A (ja) 2011-04-01 2020-10-20 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014502846A Expired - Fee Related JP6170903B2 (ja) 2011-04-01 2012-03-30 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018122610A Pending JP2018172411A (ja) 2011-04-01 2018-06-28 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
JP2020176145A Withdrawn JP2021019619A (ja) 2011-04-01 2020-10-20 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体

Country Status (37)

Country Link
US (5) US20140294832A1 (enExample)
EP (1) EP2694544B1 (enExample)
JP (4) JP6170903B2 (enExample)
KR (2) KR101995302B1 (enExample)
CN (2) CN107090046A (enExample)
AU (3) AU2012236296A1 (enExample)
BR (1) BR112013025376A2 (enExample)
CA (2) CA3068997A1 (enExample)
CL (1) CL2013002811A1 (enExample)
CO (1) CO6890074A2 (enExample)
CR (1) CR20130499A (enExample)
CU (1) CU20130128A7 (enExample)
CY (1) CY1121538T1 (enExample)
DK (1) DK2694544T3 (enExample)
DO (1) DOP2013000218A (enExample)
EA (2) EA034214B1 (enExample)
EC (1) ECSP13012913A (enExample)
ES (1) ES2722824T3 (enExample)
GT (1) GT201300229A (enExample)
HK (1) HK1243426A1 (enExample)
HR (1) HRP20190467T1 (enExample)
HU (1) HUE042706T2 (enExample)
IL (4) IL228633B (enExample)
LT (1) LT2694544T (enExample)
MX (1) MX2013011218A (enExample)
MY (2) MY165499A (enExample)
PE (1) PE20141149A1 (enExample)
PH (4) PH12013502039A1 (enExample)
PL (1) PL2694544T3 (enExample)
PT (1) PT2694544T (enExample)
RS (1) RS58633B1 (enExample)
SG (2) SG10201602606UA (enExample)
SI (1) SI2694544T1 (enExample)
TR (1) TR201905101T4 (enExample)
UA (1) UA113623C2 (enExample)
WO (1) WO2012135671A2 (enExample)
ZA (1) ZA201308169B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104984319B (zh) 2008-12-19 2025-05-09 武田药品工业株式会社 Tfpi抑制剂和使用方法
US8450275B2 (en) 2010-03-19 2013-05-28 Baxter International Inc. TFPI inhibitors and methods of use
EP3260466A1 (en) 2008-12-22 2017-12-27 Novo Nordisk A/S Anti-tfpi antibodies
LT3345615T (lt) 2010-03-01 2020-02-10 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
CN107090046A (zh) * 2011-04-01 2017-08-25 拜尔健康护理有限责任公司 针对组织因子途径抑制物(tfpi)的单克隆抗体
JP2015514070A (ja) * 2012-03-21 2015-05-18 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated Tfpi阻害剤および使用方法
WO2013148248A1 (en) * 2012-03-30 2013-10-03 Bayer Healthcare Llc Protease-regulated antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2970499B1 (en) 2013-03-15 2022-08-10 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
EP2970497B1 (en) 2013-03-15 2017-10-25 Bayer HealthCare LLC Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
JP6584397B2 (ja) * 2013-07-19 2019-10-02 ノヴォ ノルディスク アー/エス 凝血促進活性を誘発することができる組織因子経路インヒビターのn末端部分を認識する抗体
JP6783754B2 (ja) * 2014-09-17 2020-11-11 ノヴォ ノルディスク アー/エス 組織因子経路インヒビター(1〜161)上の2つのエピトープに結合する能力がある抗体
CA2977621C (en) * 2015-02-25 2021-11-23 Mogam Institute For Biomedical Research Antibody binding to tfpi and composition comprising the same
CN107922506B (zh) * 2015-08-19 2021-11-09 辉瑞公司 组织因子途径抑制剂抗体及其用途
WO2020021890A1 (ja) * 2018-07-25 2020-01-30 ソニー株式会社 血液凝固系解析装置
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP3260466A1 (en) * 2008-12-22 2017-12-27 Novo Nordisk A/S Anti-tfpi antibodies
LT3345615T (lt) * 2010-03-01 2020-02-10 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
CN107090046A (zh) * 2011-04-01 2017-08-25 拜尔健康护理有限责任公司 针对组织因子途径抑制物(tfpi)的单克隆抗体
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations

Similar Documents

Publication Publication Date Title
JP2017113019A5 (enExample)
JP2017500018A5 (enExample)
JP2020501532A5 (enExample)
JP2020500538A5 (enExample)
JP2014221758A5 (enExample)
JP2019535763A5 (enExample)
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
JP2018501197A5 (enExample)
JP2016020389A5 (enExample)
JP2015503909A5 (enExample)
JP2016529229A5 (enExample)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2015514110A5 (enExample)
JP2020536109A5 (enExample)
JP2017533694A5 (enExample)
JP2018535650A5 (enExample)
JP2010521147A5 (enExample)
JP2017501129A5 (enExample)
JP2016519650A5 (enExample)
JP2011157378A5 (enExample)
JP2016502515A5 (enExample)
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
JP2015529641A5 (enExample)
JP2019510739A5 (enExample)
JP2020521478A5 (enExample)